UNITY Biotechnology
OverviewSuggest Edit
Unity Biotechnology designs therapeutics that prevent various diseases of aging. The company focuses on clearing senescent cells and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
| Type | Public | |
| Founded | 2009 | |
| HQ | South San Francisco, CA, US | Map |
| Website | unitybiotechnology.com | |
| Employee Ratings | More |
Recent NewsAll News
- UNITY Biotechnology Reports Granting of New Employment Inducement Awards
- UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors
- UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
- UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
Key People/Management at UNITY Biotechnology
Keith R. Leonard
Chairman
Nathaniel David
Co-Founder and President, Director
Lynne Sullivan
Chief Financial Officer
Jamie Dananberg
Chief Medical Officer
Dan Marquess
Chief Scientific Officer
Susan Lundeen
Senior Vice President of People
UNITY Biotechnology Office Locations
UNITY Biotechnology has offices in South San Francisco and Brisbane
South San Francisco, CA, US (HQ)
285 E Grand Ave
Brisbane, CA, US
3280 Bayshore Blvd
UNITY Biotechnology Financials and Metrics
UNITY Biotechnology Revenue
| USD | |
|---|---|
Net income (Q3, 2020) | (27.6m) |
EBIT (Q3, 2020) | (24.6m) |
Market capitalization (11-Jan-2021) | 318.0m |
Closing stock price (11-Jan-2021) | 6.0 |
Cash (30-Sept-2020) | 48.6m |
EV | 293.7m |
UNITY Biotechnology's current market capitalization is $318 m.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 3.5m | 3.8m | 4.4m | 4.5m | 5.0m | 5.7m | 6.0m | 6.3m | 6.5m |
R&D expense | 13.0m | 15.2m | 14.4m | 16.5m | 18.5m | 17.8m | 19.3m | 16.1m | 18.8m |
Operating expense total | 16.5m | 19.0m | 18.7m | 21.0m | 23.4m | 23.5m | 25.2m | 22.4m | 25.4m |
EBIT | (16.5m) | (20.8m) | (19.4m) | (19.7m) | (24.5m) | (22.4m) | (27.2m) | (23.3m) | (24.6m) |
Annual
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (16.1m) | (36.1m) | (54.5m) | (18.8m) | (42.4m) | (64.1m) | (28.0m) | (46.7m) | |
Depreciation and Amortization | 502.0k | 1.0m | 1.6m | 637.0k | 1.3m | 1.9m | 903.0k | 1.8m | 2.6m |
Accounts Payable | 1.8m | (633.0k) | 91.0k | (776.0k) | 391.0k | (331.0k) | (1.3m) | (1.3m) | (966.0k) |
Cash From Operating Activities | (11.9m) | (29.9m) | (43.8m) | (20.6m) | (39.9m) | (56.7m) | (25.1m) | (44.4m) | (61.6m) |
| USD | Q1, 2018 |
|---|---|
Financial Leverage | -1.5 x |
UNITY Biotechnology Cybersecurity Score
UNITY Biotechnology Environment, Social & Governance (ESG) Ratings
UNITY Biotechnology Online and Social Media Presence
3.23k Twitter followers
UNITY Biotechnology has 3.23k Twitter Followers. The number of followers has increased 4.1% month over month and increased 7.1% quarter over quarter
UNITY Biotechnology's Trends
Twitter Engagement Stats for @UnityBiotech
147
Tweets
96
Following
3.2k
Followers
5
Tweets last 30 days
7.2
Avg. likes per Tweet
100%
Tweets with engagement
UNITY Biotechnology News and Updates
December 16, 2020
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from December 1, 2020 through December 15, 2020, the Board of Directors…
December 14, 2020
UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board
November 04, 2020
UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020.
September 15, 2020
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
- Corporate restructuring to extend cash runway through mid-2022 and key milestones -
August 18, 2020
Thinking about buying stock in Immatics NV, Biocept Inc, LMP Automotive, Unity Biotechnology, or Barrick Gold Corp?
NEW YORK, Aug. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMTX, BIOC, LMPX, UBX, and GOLD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 31, 2020
UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June…
UNITY Biotechnology Blogs
October 12, 2020
UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
SAN FRANCISCO , Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that the first patient has been dosed in a Phase 1 study of UBX1325
September 04, 2020
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
SAN FRANCISCO , Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the
August 17, 2020
UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee
UBX0101 failed to meet 12-week primary endpoint Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near-term UNITY to hold investor and analyst conference call today, Monday, August 17,
August 04, 2020
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
Content Import
Tue, 08/04/2020 - 16:07
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
August 4, 2020 at 4:05 PM EDT
This release is a backfill from a News Wire
…
July 29, 2020
UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
SAN FRANCISCO , July 29, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended
July 24, 2020
UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
SAN FRANCISCO , July 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended
UNITY Biotechnology Frequently Asked Questions
When was UNITY Biotechnology founded?
UNITY Biotechnology was founded in 2009.
Who are UNITY Biotechnology key executives?
UNITY Biotechnology's key executives are Keith R. Leonard, Nathaniel David and Lynne Sullivan.
How many employees does UNITY Biotechnology have?
UNITY Biotechnology has 7 employees.
Who are UNITY Biotechnology competitors?
Competitors of UNITY Biotechnology include Epirium Bio, Urovant Sciences and Abiogen Pharma.
Where is UNITY Biotechnology headquarters?
UNITY Biotechnology headquarters is located at 285 E Grand Ave, South San Francisco.
Where are UNITY Biotechnology offices?
UNITY Biotechnology has offices in South San Francisco and Brisbane.
How many offices does UNITY Biotechnology have?
UNITY Biotechnology has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies